Zavesca
How to Report an Adverse Reaction to a Medication »
"Potential drug treatments are tested on paper, in laboratories and eventually in thousands of people. But every drug that goes through this cycle – every drug that FDA approves – carries some risk. One of the first lines of defense against "...
Read the How to Report an Adverse Reaction to a Medication article »
Zavesca
OVERDOSE
In the clinical development program for ZAVESCA® (miglustat) , no patient experienced an overdose of study drug. However, ZAVESCA® (miglustat) has been administered at doses of up to 3000 mg/day (approximately 10 times the recommended starting dose administered to Gaucher patients) for up to six months in Human Immunodeficiency Virus (HlV)-positive patients. Adverse events observed in the HIV studies included granulocytopenia, dizziness, and paresthesia. Leukopenia and neutropenia have also been observed in a similar group of patients receiving 800 mg/day or above.
CONTRAINDICATIONS
ZAVESCA® (miglustat) is contraindicated in patients who have demonstrated hypersensitivity to the active substance or any of the excipients.
Pregnancy Category X
Miglustat may cause fetal harm when administered to a pregnant woman. In female rats given miglustat by oral gavage at doses of 20, 60, 180 mg/kg/day beginning 14 days before mating and continuing through gestation day 17 (organogenesis), decreased live births including complete litter loss and decreased fetal weight was observed in the mid-and high-dose groups (systemic exposures ≥ 2 times the human therapeutic systemic exposure based on body surface area comparison). In pregnant rats given miglustat by oral gavage at doses of 20, 60, 180 mg/kg/day from gestation day 6 through lactation (postpartum day 20), dystocia and delayed parturition were observed in the mid- and high-dose groups (systemic exposures ≥ 2 times the human therapeutic systemic exposure, based on body surface area comparison), in addition decreased live births and pup body weights were observed at > 20 mg/kg/day (systemic exposures less than the human therapeutic systemic exposure, based on body surface area comparison).
In pregnant rabbits given miglustat by oral gavage at doses of 15, 30, 45 mg/kg/day during gestation days 6-18 (organogenesis), maternal death and decreased body weight gain were observed at 15 mg/kg/day (systemic exposures less than the human therapeutic systemic exposure, based on body surface area comparisons).
ZAVESCA® (miglustat) is contraindicated in women who are or may become pregnant. If this drug is administered to a woman with reproductive potential, the patient should be apprised of the potential hazard to a fetus.
Last reviewed on RxList: 1/11/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Zavesca Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
